Sustained therapeutic efficacy and safety of oral propafenone for treatment of chronic ventricular arrhythmias: a 2-year experience.

[1]  B. Gersh,et al.  Propafenone for the treatment of refractory complex ventricular ectopic activity. , 1986, Mayo Clinic proceedings.

[2]  M. Murphy,et al.  Efficacy of propafenone compared with quinidine in chronic ventricular arrhythmias. , 1985, The American journal of cardiology.

[3]  E. Ambrosioni,et al.  Comparison of propafenone and disopyramide for treatment of chronic ventricular arrhythmias: placebo-controlled, double-blind, randomized crossover study. , 1985, American heart journal.

[4]  E. Ambrosioni,et al.  Propafenone for refractory ventricular arrhythmias: correlation with drug plasma levels during long-term treatment. , 1984, The American journal of cardiology.

[5]  S. Rabkin,et al.  Propafenone for the treatment of severe ventricular arrhythmias. , 1984, Canadian Medical Association journal.

[6]  J. Doherty,et al.  Effect of propafenone in patients with stable ventricular arrhythmias. , 1984, American heart journal.

[7]  B. Lown,et al.  Propafenone: a new agent for ventricular arrhythmia. , 1984, Journal of the American College of Cardiology.

[8]  B. Lown,et al.  Long-term mexiletine for ventricular arrhythmia. , 1984, American heart journal.

[9]  G. Stiles,et al.  Demonstration of beta adrenoceptor blockade by propafenone hydrochloride: clinical pharmacologic, radioligand binding and adenylate cyclase activation studies. , 1984, The Journal of pharmacology and experimental therapeutics.

[10]  N. El-Sherif,et al.  Electrophysiologic effects of propafenone on canine ischemic cardiac cells. , 1981, The American journal of cardiology.

[11]  B. Lown,et al.  Propafenone: noninvasive evaluation of efficacy. , 1984, The American journal of cardiology.

[12]  R. Asinger,et al.  A controlled trial of propafenone for treatment of frequent and repetitive ventricular premature complexes. , 1984, The American journal of cardiology.

[13]  A. Shah,et al.  Efficacy of mexiletine in chronic ventricular arrhythmias compared with quinidine: a single-blind, randomized trial. , 1984, The American journal of cardiology.

[14]  D. Salerno,et al.  Double-blind placebo-controlled evaluation of propafenone in suppressing ventricular ectopic activity. , 1984, The American journal of cardiology.

[15]  S. Connolly,et al.  Clinical efficacy and electrophysiology of oral propafenone for ventricular tachycardia. , 1983, The American journal of cardiology.

[16]  S. Connolly,et al.  Clinical pharmacology of propafenone. , 1983, Circulation.

[17]  M. Murphy,et al.  The Safety and Efficacy of Propafenone in Suppressing Ventricular Ectopy , 1983 .

[18]  S. Harapat,et al.  High-performance liquid chromatographic analysis of propafenone in human plasma samples. , 1982, Journal of chromatography.

[19]  A. Mugelli,et al.  Electrophysiological and Antiarrhythmic Properties of Propafenon in Isolated Cardiac Preparations , 1981, Journal of cardiovascular pharmacology.

[20]  A. Castellanos,et al.  Relationship Between Plasma Levels of Procainamide, Suppression of Premature Ventricular Complexes and Prevention of Recurrent Ventricular Tachycardia , 1981, Circulation.

[21]  A. DeMaria,et al.  The adverse prognostic significance of an abnormal thallium myocardial perfusion scintigram , 1981 .

[22]  Joel Morganroth,et al.  Long-Term Ambulatory Electrocardiographic Recording in the Determination of Efficacy of New Antiarrhythmic Agents , 1981 .